<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Physiol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Physiol. (Lond.)</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1469-7793</journal-id>
<journal-id journal-id-type="publisher-id">TJP</journal-id>
<journal-id journal-id-type="hwp">jphysiol</journal-id>
<journal-title-group>
<journal-title>The Journal of Physiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3751</issn>
<issn pub-type="epub">1469-7793</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30132892</article-id>
<article-id pub-id-type="pmc">6187029</article-id>
<article-id pub-id-type="doi">10.1113/JP276304</article-id>
<article-id pub-id-type="publisher-id">TJP13211</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Research Paper</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Inhibition of GluN2A NMDA receptors ameliorates synaptic plasticity deficits in the <italic>Fmr1<sup>−/y</sup></italic> mouse model</article-title>
<alt-title alt-title-type="left-running-head">C. J. Lundbye and others</alt-title>
<alt-title alt-title-type="right-running-head">GluN2A NMDA receptors and synaptic plasticity</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="tjp13211-cr-0001">
<name>
<surname>Lundbye</surname>
<given-names>Camilla J.</given-names>
</name>
<xref ref-type="aff" rid="tjp13211-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="tjp13211-note-0001">
<sup>†</sup>
</xref>
<xref ref-type="bio" rid="d35e55">*</xref>
</contrib>
<contrib contrib-type="author" id="tjp13211-cr-0002">
<name>
<surname>Toft</surname>
<given-names>Anna Karina H.</given-names>
</name>
<xref ref-type="aff" rid="tjp13211-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="tjp13211-cr-0003">
<name>
<surname>Banke</surname>
<given-names>Tue G.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8417-4400</contrib-id>
<address>
<email>tbanke@gmail.com</email>
</address>
<xref ref-type="aff" rid="tjp13211-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="tjp13211-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Institute of Biomedicine – Physiology</named-content>
<institution>Aarhus University</institution>
<named-content content-type="post-code">DK‐8000</named-content>
<named-content content-type="city">Aarhus</named-content>
<country country="DK">Denmark</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Corresponding author</bold> T. G. Banke: <italic>Institute of Biomedicine—Physiology, Aarhus University, DK‐8000 Aarhus, Denmark</italic>. Email: <email>tbanke@gmail.com</email></corresp>
<fn id="tjp13211-note-0001">
<label>†</label>
<p>Edited by: Ole Paulsen &amp; Shona Chattarji</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>15</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>596</volume>
<issue>20</issue>
<issue-id pub-id-type="doi">10.1113/tjp.2018.596.issue-20</issue-id>
<fpage>5017</fpage>
<lpage>5031</lpage>
<history>
<date date-type="received">
<day>07</day>
<month>7</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Journal compilation &#x000a9; 2018 The Physiological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The Authors. The Journal of Physiology © 2018 The Physiological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:TJP-596-5017.pdf" xlink:type="simple"></self-uri>
<abstract>
<sec id="tjp13211-sec-0010">
<title>Key points</title>
<p>
<list id="tjp13211-list-0001" list-type="bullet"><list-item><p>Fragile X syndrome (FXS) is a genetic condition that is the most common form of inherited intellectual impairment and causes a range of neurodevelopmental complications including learning disabilities and intellectual disability and shares many characteristics with autism spectrum disorder (ASD).</p></list-item><list-item><p>In the FXS mouse model, <italic>Fmr1<sup>−/y</sup></italic>, impaired synaptic plasticity was restored by pharmacologically inhibiting GluN2A‐containing NMDA receptors but not GluN2B‐containing receptors.</p></list-item><list-item><p>Similar results were obtained by crossing <italic>Fmr1<sup>−/y</sup></italic> with GluN2A knock‐out (<italic>Grin2A<sup>−/−</sup></italic>) mice.</p></list-item><list-item><p>These results suggest that dampening the elevated levels of GluN2A‐containing NMDA receptors in <italic>Fmr1<sup>−/y</sup></italic> mice has the potential to restore hyperexcitability of the neural circuitry to (a more) normal‐like level of brain activity.</p></list-item></list>
</p>
</sec>
<sec id="tjp13211-sec-0020">
<title>Abstract</title>
<p>NMDA receptors (NMDARs) play important roles in synaptic plasticity at central excitatory synapses, and dysregulation of their function may lead to severe disorders such Fragile X syndrome (FXS). FXS is caused by transcriptional silencing of the FMR1 gene followed by lack of the encoding protein. Here we examined the effects of pharmacological and genetic manipulation of hippocampal NMDAR functions in long‐term potentiation (LTP) and depression (LTD). We found impaired NMDAR‐dependent LTP in the Fmr1‐deficient mice, which could be fully restored when GluN2A‐containing NMDARs was pharmacological inhibited. Interestingly, similar LTP effects were observed when the GluN2A gene (<italic>Grin2a</italic>) was deleted in <italic>Fmr1<sup>−/y</sup></italic> mice (<italic>Fmr1<sup>−/y</sup></italic>/<italic>Grin2a<sup>−/−</sup></italic> double knockout). In addition, GluN2A inhibition improved elevated mGluR5‐dependent LTD to normal level in the <italic>Fmr1<sup>−/y</sup></italic> mouse. These findings suggest that GluN2A is a promising target in FXS research that could help us better understand the disorder.</p>
</sec>
</abstract>
<abstract abstract-type="toc" id="d35e252">
<title>Key points</title>
<p>
<list id="tjp13211-list-0002" list-type="bullet"><list-item><p>Fragile X syndrome (FXS) is a genetic condition that is the most common form of inherited intellectual impairment and causes a range of neurodevelopmental complications including learning disabilities and intellectual disability and shares many characteristics with autism spectrum disorder (ASD).</p></list-item><list-item><p>In the FXS mouse model, <italic>Fmr1<sup>−/y</sup></italic>, impaired synaptic plasticity was restored by pharmacologically inhibiting GluN2A‐containing NMDA receptors but not GluN2B‐containing receptors.</p></list-item><list-item><p>Similar results were obtained by crossing <italic>Fmr1<sup>−/y</sup></italic> with GluN2A knock‐out (<italic>Grin2A<sup>−/−</sup></italic>) mice.</p></list-item><list-item><p>These results suggest that dampening the elevated levels of GluN2A‐containing NMDA receptors in <italic>Fmr1<sup>−/y</sup></italic> mice has the potential to restore hyperexcitability of the neural circuitry to (a more) normal‐like level of brain activity.</p></list-item></list>
</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="tjp13211-kwd-0001">Fragile X syndrome</kwd>
<kwd id="tjp13211-kwd-0002">Glutamate receptors</kwd>
<kwd id="tjp13211-kwd-0003">GluN2A</kwd>
<kwd id="tjp13211-kwd-0004">Synaptic plasticity</kwd>
<kwd id="tjp13211-kwd-0005">tri‐heteromeric NMDA receptors</kwd>
<kwd id="tjp13211-kwd-0006">Intellectual Disability</kwd>
<kwd id="tjp13211-kwd-0007">Developmental Disability</kwd>
<kwd id="tjp13211-kwd-0008">Autism</kwd>
<kwd id="tjp13211-kwd-0009">neuropsychiatric diseases</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Riisfort</funding-source>
</award-group>
<award-group>
<funding-source>Det Frie Forskningsråd (Danish Council for Independent Research)</funding-source>
<award-id>DFF ‐ 4004‐00188</award-id>
</award-group>
<award-group>
<funding-source>Lundbeckfonden (Lundbeck Foundation)</funding-source>
<award-id>2011‐8826</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="7"></fig-count>
<table-count count="0"></table-count>
<page-count count="15"></page-count>
<word-count count="8820"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>tjp13211</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>15 October 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.0.1 mode:remove_FC converted:15.10.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group>
<fn id="tjp13211-note-0002">
<p>Present address: Department of Physiology, University of Toronto, Faculty of Medicine, Toronto, ON, M5S 1A8, Canada.</p>
</fn>
</fn-group>
</notes>
</front>
</article>
</pmc-articleset>